| Market Capitalization (Millions $) |
537 |
| Shares
Outstanding (Millions) |
98 |
| Employees |
79 |
| Revenues (TTM) (Millions $) |
22 |
| Net Income (TTM) (Millions $) |
-60 |
| Cash Flow (TTM) (Millions $) |
-5 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops innovative small molecule therapies for the treatment of cancer and other serious diseases. The company was founded in 2016 and is headquartered in Wilmington, North Carolina, with additional offices in New York City and Shanghai.
Prelude Therapeutics Inc. focuses on developing therapies that target signaling pathways that are critical for cancer growth and progression. The company's lead product candidate, PRT543, is a potent and selective inhibitor of PRMT5, an enzyme that is essential for the growth and survival of several types of cancer cells. PRT543 has shown promising preclinical activity in a variety of solid tumors and hematological malignancies, including diffuse large B-cell lymphoma, multiple myeloma, and acute myeloid leukemia.
In addition to PRT543, Prelude Therapeutics Inc. has a pipeline of other small molecule inhibitors that target key oncogenic signaling pathways, including Wnt, Notch, and Hedgehog. The company's approach is based on the belief that using a combination of targeted agents that attack different pathways may lead to more effective and durable responses in patients with cancer.
Prelude Therapeutics Inc. has a team of experienced pharmaceutical executives and scientists who have a track record of developing successful cancer therapies. The company has also established collaborations with leading academic and research institutions to accelerate the discovery and development of new therapeutics.
Overall, Prelude Therapeutics Inc. is a promising biopharmaceutical company that is focused on developing innovative therapies for the treatment of cancer and other serious diseases. With a robust pipeline of small molecule inhibitors and a team of experienced scientists and executives, the company has the potential to make a significant impact in the field of oncology.
Company Address: 175 Innovation Boulevard Wilmington 19805 DE
Company Phone Number: 467-1280 Stock Exchange / Ticker: NASDAQ PRLD
|
2.68% 